Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
lloprost · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| I-Neb - FOX | EXPERIMENTAL | Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer; followed by single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer in a cross-over fashion. A washout period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks in a cross-over fashion. |
| FOX - I-Neb | EXPERIMENTAL | Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer; followed by single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer in a cross-over fashion. A wash-out period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks in a cross-over fashion. |
| Name | Type | Description |
|---|---|---|
| lloprost(Ventavis,BAYQ6252, 20 µg/mL) | DRUG | 20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer |
| lloprost(Ventavis,BAYQ6252, 10 µg/mL) | DRUG | 10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer |
Inclusion Criteria: * Male or female aged ≥ 18 years * Current diagnosis of pulmonary hypertension (updated Dana Point Classification 1). * Current inhalative therapy with 5 µg iloprost using the I-Neb nebulizer * WHO functional class III at the time of the patient's commencement of inhalative ther...
Top 13 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 8 | PHASE3 | Sotatercept, Riociguat, Frespaciguat |
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag, Tyvaso (treprostinil) |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | selexipag, Macitentan |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606, LIQ861 Treprostinil, LIQ861 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | Levosimendan (TNX-103) |
| Inhibikase Therapeutics, Inc. | IKT | 2 | PHASE3 | IKT-001 |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Tectonic Therapeutic Inc | TECX | 2 | PHASE2 | TX45 |
| Gossamer Bio, Inc. | GOSS | 1 | PHASE3 | Seralutinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| GSK plc Sponsored ADR | GSK | 2 | PHASE1 | HS235 |
lloprost is being developed for the treatment of Pulmonary Arterial Hypertension, a cardiovascular condition. It is an investigational small molecule studied by Bayer AG. The clinical program has focused on patients with PAH, with one completed Phase 1 trial that enrolled 27 participants.
lloprost is being developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer AG is the sponsor of the clinical program for this small molecule in Pulmonary Arterial Hypertension.
lloprost is in Phase 1 clinical development. The program has one completed Phase 1 trial and no active trials at this time. It is an investigational agent and has not been approved for any indication.
lloprost has been studied in one completed Phase 1 trial, NCT02032836, titled Comparative PK PD Study in PAH Patients (Fox vs. I-Neb). The trial enrolled 27 participants with Pulmonary Arterial Hypertension across Austria and Germany. It was randomized and controlled, with no healthy volunteers.
Yes, lloprost is also known as Ventavis and BAYQ6252. The 20 µg/mL formulation is referenced in the alternative names. These names refer to the same small molecule developed by Bayer AG for Pulmonary Arterial Hypertension.